Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%+1.78%+19.51%-8.76% 66.56B
-2.04%-3.49%+49.68%+221.00% 56.51B
+1.07%+42.10%+42.10%+42.10% 42.98B
+1.99%+7.66%-49.90%-54.41% 40.46B
-1.46%-2.24%+62.74%-25.69% 31.91B
+2.07%+15.67%+169.65%-31.84% 31.65B
-1.58%+0.31%+70.98%+82.98% 23.35B
+3.08%+13.05%+9.63%+195.27% 19.46B
-0.13%+3.03%+66.64%+132.04% 17.18B
Average +0.10%+8.76%+49.00%+61.41% 36.67B
Weighted average by Cap. -0.23%+7.31%+43.19%+53.60%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-